1	Temporal inhibition of autophagy reveals segmental reversal of aging with		
2	increased cancer risk		
3	Liam D Cassidy ¹ , Andrew RJ Young ¹ , Christopher NJ Young ² , Elizabeth J Soilleux ³ ,		
4	Edward Fielder ⁴ , Bettina M Weigand ⁴ , Rebecca Brais ⁵ , Kimberley A Wiggins ⁶ , Murray		
5	CH Clarke ⁶ , Diana Jurk ^{4,7} , Joao F Passos ^{4,7} , Masashi Narita ^{1*}		
6			
7	¹ University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way,		
8	Cambridge, CB2 0RE, UK		
9	² Leicester Institute for Pharmaceutical Innovation, Faculty of Health and Life Sciences,		
10	De Montfort University, Leicester, LE1 5RR, UK		
11	³ Division of Cellular and Molecular Pathology, Department of Pathology, University of		
12	Cambridge, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ, UK		
13	⁴ Ageing Research Laboratories, Newcastle University Institute for Ageing, Institute for		
14	Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE4		
15	5PL, UK		
16	⁵ Department of Histopathology, Cambridge University Hospitals NHS Foundation		
17	Trust, Cambridge, UK		
18	⁶ Division of Cardiovascular Medicine, University of Cambridge, Addenbrookes		
19	Hospital, Hills Road, Cambridge CB2 0QQ, UK		
20	⁷ Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN,		
21	United States		
22	*Correspondence to Masashi.Narita@cruk.cam.ac.uk		

23 Abstract

24 Autophagy is an important cellular degradation pathway with a central role in 25 metabolism as well as basic quality control, two processes inextricably linked to aging. 26 A decrease in autophagy is associated with increasing age, yet it is unknown if this is 27 causal in the aging process, and whether autophagy restoration can counteract these 28 aging effects. Here we demonstrate that systemic autophagy inhibition induces the 29 premature acquisition of age-associated phenotypes and pathologies in mammals. 30 Remarkably, autophagy restoration provides a near complete recovery of morbidity 31 and a significant extension of lifespan, however, at the molecular level this rescue 32 appears incomplete. Importantly autophagy-restored mice still succumb earlier due to 33 an increase in spontaneous tumor formation. Thus our data suggest that chronic 34 autophagy inhibition confers an irreversible increase in cancer risk and uncovers a 35 biphasic role of autophagy in cancer development being both tumor suppressive and 36 oncogenic, sequentially.

37 Main Text

38 Physiological aging is a complex and multifaceted process associated with the 39 development of a wide array of degenerative disease states. While there is no 40 accepted singular underlying mechanism of aging, a combination of genetic, 41 environmental and metabolic factors have been shown to alter the aging process¹⁻³. 42 As such, lifestyle and pharmacological regimens have been proposed that may offer 43 health- and or life-span benefits⁴⁻⁶. However, despite chronological aging representing 44 the greatest risk factor for pathological conditions as diverse as neurodegeneration, 45 cancer, and cardiovascular disease, there is a paucity of genetic mammalian models 46 that allow for dynamic modulation of key processes in mammalian aging.

47

48 Autophagy is an evolutionarily conserved bulk cellular degradation system that 49 functions to breakdown and recycle a wide array of cytoplasmic components from 50 lipids, proteins and inclusion bodies, to whole organelles (e.g. mitochondria). 51 Importantly a reduction in autophagic flux (the rate at which autophagosomes form and 52 breakdown cellular contents) is associated with increasing age in mammals⁷. Evidence 53 from lower organisms suggests that autophagy inhibition can negate the positive-54 effects of regimens that extend lifespan, such as calorie restriction, rapamycin 55 supplementation, and mutations in insulin signalling pathways⁸⁻¹⁰.

56

In mice, the constitutive promotion of autophagy throughout lifetime has been shown to extend health- and life-span in mammalian models^{11,12}. These studies have provided hitherto missing evidence that autophagic flux can impact on mammalian longevity and supports the notion that the pharmacological promotion of autophagy may extend health-, and potentially life-span, in humans. However, whether a reduction in autophagy is sufficient to induce phenotypes associated with aging, and whether these effects can be reversed by restoring autophagy has to date not been addressed.

64 Considering that the therapeutic window for pharmacological intervention to counteract 65 aging, and age-related diseases, will be later in life (as opposed to from conception), 66 after autophagic flux has declined, it is critical to understand how the temporal 67 modulation (inhibition and restoration) of autophagy may impact on longevity and 68 health.

69

70 To address these questions, we use two doxycycline (dox) inducible shRNA mouse 71 models that target the essential autophagy gene Atg5 (Atg5i mice) to demonstrate that 72 autophagy inhibition in young adult mice is able to drive the development of aging-like 73 phenotypes and reduce longevity. Importantly we confirm that the restoration of 74 autophagy is associated with a substantial restoration of health- and life-span, however 75 this recovery is incomplete. Notably the degree of recovery is segmental, being 76 dependent on both the tissue and metric analysed. A striking consequence of this 77 incomplete restoration is that autophagy restored mice succumb to spontaneous tumor 78 formation earlier and at an increased frequency than control mice, a phenotype not 79 observed during autophagy inhibition alone. As such our studies indicate that despite 80 the significant benefit, autophagy reactivation may also promote tumorigenesis in 81 advanced ageing context.

82

83 Reduced lifespan in Atg5i mice

Previously, we have reported the development of a highly efficient dox inducible shRNA mouse model targeting Atg5 (Atg5i) ¹³ that phenocopies tissue-specific Atg5 knockout (KO) mice. These mice lack brain expression of the shRNA and as such do not suffer from the lethal neurotoxic effects that characterise systemic autophagy knockout mice^{14,15}, and enable us to perform longitudinal studies that were previously unachievable *in vivo*.

90

91 A common caveat of many mouse models is that genetic manipulations are often 92 present during embryogenesis. Thus, any phenotypes that manifest are a combination 93 of both developmental and tissue homeostasis effects. To avoid the generation of 94 these compound effects, Atg5i mice were aged until eight-weeks (young adults) before 95 being transferred to a dox-containing diet and followed to assess overall survival. Atg5i 96 mice on long-term dox (LT-Atg5i) had a median survival of ~six months on dox (Male 97 185 days; Female 207 days on dox) with no apparent sex bias (Fig. 1a-c and 98 Supplementary Fig. 1a).

99

100 In comparison to littermate controls, LT-Atq5i mice experienced a progressive 101 deterioration, initially presenting with a reduction in coat condition within the first few 102 weeks and a reduction in weight gain that became more pronounced over the life of 103 the animal (Fig. 1d, e and Supplementary Fig. 1b). The majority of mice eventually 104 succumbed to a general morbidity characterised by lethargy, piloerection, and a 105 decrease in body condition, wherein they have to be sacrificed. As previously 106 described with naturally aged colonies¹⁶, LT-Atg5i mice also appeared susceptible to 107 eye infections and ulcerative dermatitis, the later being primarily localised to the ears 108 and neck and ranging from mild to severe (Fig. 1f and Supplementary Fig. 1c, 109 respectively).

110

A singular cause of death in LT-Atg5i mice is difficult to determine and it is most likely of multifactorial aetiology across the cohort. At necropsy, all mice displayed hepatomegaly and splenomegaly in comparison to age and sex matched controls, consistent with phenotypes associated with tissue specific knockout mice¹⁷⁻¹⁹. Elevated serum ALT and reduced levels of serum albumin were present throughout dox administration of Atg5i mice, yet were altered further at the time of death only in a subset of samples (Supplementary Fig. 1f, g, yellow circles). Consistent with this, an

increase in serum bilirubin levels was only observed at the time of death within this same subset of mice (Supplementary Fig. 1h, yellow circle). These data suggest that severe liver failure occurs in only a fraction.

121

122 Interestingly serum creatinine levels, a marker of kidney function, also displayed an 123 increase only in a different subset of LT-Atg5i mice at the time of death, although they 124 were not generally high during dox administration (Supplementary Fig. 2a). Loss of 125 autophagy also correlated with a general thickening of the basement membrane and 126 the presence of sclerotic (Supplementary Fig. 2b) and enlarged glomeruli 127 (Supplementary Fig. 2c, d) in comparison to age-matched tissue samples, indicative 128 of degenerative kidney disorder. LT-Atg5i mice also stained positively for the build-up 129 of toxic amyloid proteins and the autophagy adaptor protein p62/Sqstm1, a condition 130 normally associated with advancing age in humans (Supplementary Fig. 2e, f). These 131 data suggest that, similar to the liver, systemic autophagy defect causes age-related 132 degenerative alterations in kidney, yet only a distinct subset progresses to renal failure 133 on death. In addition to this stochastic development of organ failure, LT-Atg5i mice 134 universally presented with cardiomyopathy (Supplementary Fig. 2g). Histological 135 examination highlighted the presence of enlarged, degenerate and vacuolated 136 cardiomyocytes, in addition to the presence of cardiac fibrosis (Fig. 1g).

137

Together, our data suggest that, despite the stereotypic premature death, LT-Atg5i mice suffered from a heterogeneous set of tissue degenerative disorders that appear to have contributed to an increase in mortality. Of note, there was no evidence of overt tumor development in these mice.

142

143 Autophagy inhibition is associated with accelerated aging

144 All LT-Atg5i mice displayed evidence of kyphosis after four months of dox treatment 145 that became progressively more pronounced as the animals aged until death, whilst 146 16/28 LT-Atq5i mice displayed evidence of premature greying to varying degrees (Fig. 147 1h). Furthermore LT-Atg5i mice displayed evidence of extramedullary hematopoiesis 148 (Fig. 2a) and immune aggregations, commonly seen in aged mouse colonies, were 149 also found in the liver, lungs and kidneys but were generally absent in age matched 150 controls, although incidence of these increased in frequency with increasing age 151 (Supplementary Fig. 3a).

152

As previously described in hematopoietic Atg5 KO mice, LT-Atg5i mice also displayed an increase in cellularity of the peripheral immune system ^{18,20} (Supplementary Fig. 3b) with a myeloid skewing (Fig. 2b) reminiscent of age-associated chronic inflammation. This 'inflamm-aging' phenotype was further supported by an increase in serum TNF and IL-6 in LT-Atg5i mice in comparison to control (Fig. 2c).

158

159 Skeletal muscle exhibits an age-related decline and autophagy has been reported to 160 be required for the maintenance of Pax7 positive satellite cells (myogenic precursors) 161 ²¹. In accordance, LT-Atg5i mice displayed evidence of skeletal muscle degeneration 162 with the presence of smaller fibres, a reduction in the population of Pax7 positive 163 satellite cells, and an increase in central nucleation in comparison to age-matched 164 littermate control mice (Fig. 2d-g). Central nucleation represents muscle fibre 165 regeneration after acute muscle injury but an increase in basal frequency of centrally 166 nucleated myofibres is also a sign of sarcopenia at geriatric age both in mice and human²². Additionally, LT-Atq5i muscle fibres displayed increased staining positivity 167 168 for the mitochondrial marker TOM20 indicative of increased mitochondrial mass and a 169 reduction in autophagy mediated turnover (Fig. 2h).

170

171 The accumulation of senescent cells is considered a key marker of chronological 172 aging. Autophagy has been reported to have context dependent and sometimes 173 opposing roles during cellular senescence: typically basal autophagy is considered to 174 promote fitness and its loss may promote senescence, whereas in oncogene-induced 175 senescence, autophagy may be important for the establishment of senescent 176 phenotypes ²³⁻²⁶. To determine if the systemic loss of basal autophagy is sufficient to 177 drive the establishment of cellular senescence in vivo we performed western blotting 178 across a number of tissues from 4-month dox treated LT-Atg5i mice and found an 179 increased staining pattern for key senescence markers (i.e. p16, p21, and p53) (Fig. 180 3a-c and Supplementary Fig. 3c). Additionally, whole mount senescence-associated 181 beta-galactosidase staining from 6-month treated livers highlighted a marked increase 182 in staining patterns in comparison to LT-Control mice (Fig. 3d). Histologically, nuclear 183 accumulation of p21 was also evident, particularly in hepatocytes with enlarged 184 morphology (Fig. 3d). Furthermore LT-Atg5i mice display a significant increase in both 185 the abundance and frequency of telomere-associated y-H2AX foci (TAF), which have 186 been shown to correlate with senescence, increasing age and mitochondrial 187 dysfunction (Fig. 3e, f) ²⁷⁻²⁹. These data reinforce the age acceleration upon systemic 188 autophagy reduction.

189

Of note, similar gross phenotypic results were also seen in mice with a second hairpin targeting Atg5 (LT-Atg5i_2). LT-Atg5i_2 mice display evidence of premature aging-like phenotypes (Supplementary Fig. 4a-c), however the appearance of these phenotypes is delayed in comparison to LT-Atg5i mice, seemingly due to a hypomorphic reduction in Atg5. Accordingly, these mice displayed the accumulation of p62/Sqstm1 and LC3 in multiple tissues but at lower levels in comparison to LT-Atg5i mice, and did not display phenotypes associated with complete Atg5 knockout mice, including

197 hepatomegaly and splenomegaly (Supplementary Fig. 4d-f). These findings in 198 particular are important as they establish that the reduction in longevity and presence 199 of aging phenotypes is not dependent on the hepatomegaly and splenomegaly 200 phenotypes encountered in the original LT-Atg5i mouse strain with the highest degree 201 of autophagy inhibition.

202

203 Combined these data support a role for basal autophagy in maintaining tissue and 204 organismal homeostasis and provide evidence that causally links autophagy inhibition 205 to the induction of aging-like phenotypes in mammals.

206

207 Autophagy Restoration Partially Reverses Accelerated Aging-like Phenotypes

We next sought to determine whether autophagy restoration alone is able to reverse the aging-like phenotypes by removing dox from the diet. Eight-week old Atg5i and control mice treated with dox for four months, the point at which they universally presented with kyphosis, were switched back to a diet absent of dox leading to a restoration in Atg5 levels and autophagy (termed R-Atg5i cohort) ¹³. Interestingly the senescence marker p21 remained elevated across a number of tissues 2 months post dox removal (Fig. 4a, b).

215

216 An increase in chronological age is generally associated with the deviations in multiple 217 health parameters that when measured can be combined into a clinical 'frailty-score' 218 ³⁰. As expected R-Atg5i mice displayed an initial increase in their frailty scores during 219 autophagy inhibition in comparison to littermate controls, yet once mice have been 220 switched back to a diet absent of dox, the frailty scores displayed a significant decrease 221 over the next four months (Fig. 4c, Supplementary Movie. 1). In contrast, LT-Atg5i mice 222 treated on dox for 6 months (median survival is around ~6 months on dox) continued 223 to display a significant difference in their frailty scores, while almost all LT-Atg5i mice had already succumbed by eight-months (Fig. 4c). A similar increase in frailty was also
noted in the LT-Atg5i_2 cohorts (Supplementary Fig. 4b). The penetrant kyphosis
phenotype was largely irreversible, however 3/26 R-Atg5i mice did show evidence of
recovery from kyphosis, while no mice displayed a reversal of the greying phenotypes.
As such, while autophagy inhibition *in vivo* appears to promote frailty, autophagy
restoration is seemingly able to substantially reverse this effect.

230

231 Remarkably the profound immune-associated phenotypes that we observed in 232 autophagy-deficient LT-Atq5i mice were reversed in R-Atq5i mice. Serum markers of 233 inflammation and WBC counts were indistinguishable between R-Atq5i and R-Control 234 mice (Fig. 4d, e and Supplementary Fig. 5a). However, it should be noted that there 235 was a trend towards a larger red blood cell distribution width (RDW) in aged R-Atg5i 236 mice removed from dox for 8 months (14 months old), which has previously been linked 237 to a range of diseases and an increased risk of acute myeloid leukemia (AML) (Fig. 4f) 238 ³¹. Additionally, R-Atg5i livers displayed a complete reversal of hepatomegaly and 239 serum ALT levels (Supplementary Fig. 5c and c). The kidneys of R-Atq5i mice 240 appeared to recover from autophagy inhibition and lacked evidence of sclerotic and 241 enlarged glomeruli (Supplementary Fig. 5 d-f). Consistently, serum albumin levels 242 displayed evidence of normalisation, although there was still a trend for reduced levels 243 in R-Atg5i mice at the time point tested, suggesting that liver and/or kidney functions 244 are largely recovered, if not completely (Supplementary Fig. 5g).

245

Similarly, the protein aggregation marker p62/SQSTM1 in the liver appeared much reduced in R-Atg5i mice in comparison to the LT-Atg5i mice, yet a small but substantial number of cells still exhibited a marked accumulation of p62 aggregation in R-Atg5i mice that had been off dox for four months (Fig. 5a). Additionally, R-Atg5i livers were also found to contain the presence of ceroid-laden macrophages and lipofuscin positivity, pigments known to increase with age and not seen in age-matched controls

mice (Fig. 5b). Importantly, and in accordance with this partial restoration phenotype,
molecular markers of aging such as TAF also remained significantly elevated in RAtg5i mice. This is consistent with the persistent nature of telomeric DNA damage,
which is reported to be irreparable^{27,32}. Together with other senescence markers (Fig.
4b), these data suggest that a portion of the cellular damage caused by a chronic block
in autophagy is irreversible (Fig. 5c).

258

259 Morphological analysis of skeletal muscle from R-Atq5i mice with autophagy restored 260 suggests that muscle fibre size and morphology display no sign of recovery at the 261 timepoint analysed (Fig. 5d, e and Supplementary Fig. 6a, b). However central 262 nucleation and satellite cell frequency appeared to display a heterogeneous pattern, 263 with evidence of recovery apparent in some individuals (Fig. 5f. g). As expected with 264 Atg5 restoration, mitochondrial levels as determined by Tom20 positivity were restored 265 to control levels (Fig. 5h). Additionally, the cardiac fibrosis observed LT-Atg5i mice 266 appears to still be present four months post dox removal in R-Atg5i cohorts 267 (Supplementary Fig. 6c). Together these data suggest that autophagy restoration may 268 have tissue and pathology specific limitations in the capacity to recover from the tissue 269 and cellular damage induced upon its inhibition. Crucially, whilst some tissues, such 270 as the liver, appear to recover, they are still associated with age-associated 271 pathologies at the molecular level.

272

273 Accelerated tumor development in R-Atg5i mice

As R-Atg5i mice displayed some evidence of organismal rejuvenation and an increase in overall health, we sought to determine if autophagy restoration is able to reinstate natural longevity to the level seen in littermate control mice, or whether the damage accumulation impacting on lifespan was irreversible. Remarkably, while the life-span of R-Atg5i mice was significantly extended in comparison to LT-Atg5i mice (median survival 493 days versus 185 days since treatment began, respectively), it was also

280 significantly shorter than the R-Control cohorts (Fig. 6a). In marked contrast to LT-281 Atg5i mice, the cause of death was predominantly associated with the development of 282 tumors with an increased frequency and at earlier timepoints (Fig. 6b-d). Of note a 283 whole-body mosaic Atg5 knockout mouse model has been previously reported to only 284 develop liver adenomas but without any malignant tumors³³. Together, our data 285 suggest that a temporary period of autophagy inhibition may be enough to induce 286 irreversible cellular damage, which might facilitate tumor development cooperatively 287 with the restoration of autophagy.

288

289 Discussion

290 While the rate of autophagic flux is believed to decrease with advancing age and has 291 been postulated to be a driver of aging in multicellular organisms, evidence in 292 mammals has been limited to the role of autophagy in maintaining stem cell populations^{18,21}. Such systemic organismal studies have been impossible to conduct 293 294 owing to the embryonic or neonatal lethality, and rapid neurotoxicity in adult mice, that accompanies systemic autophagy ablation^{14,34}. The temporal control and lack of brain 295 296 shRNA expression afforded by the Atg5i model have enabled us to circumvent these 297 barriers, and separate developmental from tissue homeostatic effects that cannot be 298 distinguished in aging models based on constitutive or *in utero* genetic modifications. 299 Our findings support the theory that a reduction in autophagy is sufficient to induce 300 several molecular and phenotypic characteristics associated with mammalian aging, 301 including the development of age-associated diseases and a reduction in longevity. 302 Here it is notable that our Atg5i mice phenocopy other models of aging driven by the 303 accumulation of damage and in particular mitochondrial dysfunction^{35,36}.

304

305 Several health and life-span extending regimens in mammals, such as calorie 306 restriction or pharmacological modulation, have been posited to exert their effects 307 through the regulation of autophagy^{7,37}. However, these effects are also pleiotropic in

308 nature and alter a multitude of cellular processes, making it impossible to deconvolute 309 and ascribe the role of autophagy in these settings. Whilst recent genetic models that 310 promote autophagic flux continuously throughout life have demonstrated an extension 311 of health- and life-span in mammalian systems^{11,12}, it is unclear if the damage 312 established by a loss of autophagy is sufficient for age acceleration and can be 313 reversed. If therapeutic regimens in humans are to be established later in life, once 314 autophagy-associated damage has accumulated, ascertaining the capacity for 315 autophagy restoration to repair this damage is critical. In our model, systemic 316 inflammation and frailty scores displayed a marked improvement upon autophagy 317 restoration, which resulted in increased survival. However, while some tissues (i.e. 318 liver and heart) displayed macroscopic normalisation, further analysis highlighted the 319 persistence of pathological phenotypes. Our results indicate that the reversibility of 320 markers of aging such as TAF, or macroscopic phenotypes such as greying and 321 kyphosis may not recover. It should also be noted that we have chosen a late time-322 point to restore autophagy as this provided a clear and ubiguitous distinction between 323 control and autophagy inhibited mice, shorter time points or intermittent dosing 324 regimens may display further heterogeneity in damage and recovery phenotypes.

325

326 Our unexpected finding, that the temporal inhibition of autophagy predisposes to 327 increased tumor development, provides a potential genetic explanation for the context-328 dependent role of autophagy in tumorigenesis^{38,39}: i.e. autophagy can be a tumor 329 suppressor^{33,40,41} or a tumor promoter⁴²⁻⁴⁴. The irreversible damage induced by 330 autophagy inhibition (e.g. genomic instability), might confer tumor susceptibility, while 331 autophagy activity is perhaps required for actual malignant transformation. The clinical 332 implication of our data is not limited to the advanced age state. As some 333 pathophysiological states, such as obesity, are associated with an insufficient level of 334 autophagy⁴⁵, it would be interesting to determine if obese individuals retain an

- 335 increased risk of tumor development even upon weight loss, in comparison to never
- 336 obese populations.

338 References and Notes

- 1. Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges
- 340 of ageing. *Nature* **561**, 45–56 (2018).
- 341 2. Sen, P., Shah, P. P., Nativio, R. & Berger, S. L. Epigenetic Mechanisms of
- 342 Longevity and Aging. *Cell* **166**, 822–839 (2016).
- 343 3. López-Otín, C., Galluzzi, L., Freije, J. M. P., Madeo, F. & Kroemer, G.
- 344 Metabolic Control of Longevity. *Cell* **166**, 802–821 (2016).
- 345 4. Newman, J. C. *et al.* Strategies and Challenges in Clinical Trials Targeting
- 346 Human Aging. J. Gerontol. A Biol. Sci. Med. Sci. 71, 1424–1434 (2016).
- 5. Colman, R. J. *et al.* Caloric restriction reduces age-related and all-cause
- 348 mortality in rhesus monkeys. *Nat Commun* **5**, 3557 (2014).
- 349 6. Mattison, J. A. *et al.* Impact of caloric restriction on health and survival in
- 350 rhesus monkeys from the NIA study. *Nature* **489**, 318–321 (2012).
- 351 7. Rubinsztein, D. C., Mariño, G. & Kroemer, G. Autophagy and Aging. *Cell* 146,
 352 682–695 (2011).
- 353 8. Meléndez, A. *et al.* Autophagy genes are essential for dauer development
- and life-span extension in C. elegans. *Science* **301**, 1387–1391 (2003).
- 355 9. Bjedov, I. *et al.* Mechanisms of life span extension by rapamycin in the fruit fly
- 356 Drosophila melanogaster. *Cell Metab.* **11**, 35–46 (2010).
- 357 10. Jia, K. & Levine, B. Autophagy is required for dietary restriction-mediated life
- 358 span extension in C. elegans. *Autophagy* **3**, 597–599 (2007).
- 359 11. Fernández, Á. F. *et al.* Disruption of the beclin 1-BCL2 autophagy regulatory
- 360 complex promotes longevity in mice. *Nature* **125**, 85 (2018).
- 361 12. Pyo, J.-O. et al. Overexpression of Atg5 in mice activates autophagy and
- 362 extends lifespan. *Nat Commun* **4**, 2300 (2013).
- 363 13. Cassidy, L. D. *et al.* A novel Atg5-shRNA mouse model enables temporal
- 364 control of Autophagy in vivo. *Autophagy* 1–11 (2018).
- 365 doi:10.1080/15548627.2018.1458172

- 366 14. Komatsu, M. *et al.* Loss of autophagy in the central nervous system causes
- 367 neurodegeneration in mice. *Nature* **441**, 880–884 (2006).
- 368 15. Menzies, F. M., Fleming, A. & Rubinsztein, D. C. Compromised autophagy
- and neurodegenerative diseases. *Nat. Rev. Neurosci.* **16**, 345–357 (2015).
- 370 16. Pettan-Brewer, C. & Treuting, P. M. Practical pathology of aging mice.
- 371 Pathobiol Aging Age Relat Dis 1, 393 (2011).
- 372 17. Komatsu, M. et al. Impairment of starvation-induced and constitutive
- autophagy in Atg7-deficient mice. *J Cell Biol* **169**, 425–434 (2005).
- 18. Ho, T. T. *et al.* Autophagy maintains the metabolism and function of young
- 375 and old stem cells. *Nature* **543**, 205–210 (2017).
- 376 19. Mortensen, M. *et al.* Loss of autophagy in erythroid cells leads to defective
- 377 removal of mitochondria and severe anemia in vivo. Proc. Natl. Acad. Sci. U.S.A.
- **107**, 832–837 (2010).
- 379 20. Watson, A. S. *et al.* Autophagy limits proliferation and glycolytic metabolism in
- acute myeloid leukemia. *Cell Death Discov* **1**, 371 (2015).
- 381 21. García-Prat, L. et al. Autophagy maintains stemness by preventing
- 382 senescence. *Nature* **529**, 37–42 (2016).
- 383 22. Sousa-Victor, P. et al. Geriatric muscle stem cells switch reversible
- 384 quiescence into senescence. *Nature* **506**, 316–321 (2014).
- 385 23. Young, A. R. J. *et al.* Autophagy mediates the mitotic senescence transition.
- 386 Genes Dev. 23, 798–803 (2009).
- 387 24. Narita, M. et al. Spatial coupling of mTOR and autophagy augments secretory
- 388 phenotypes. Science **332**, 966–970 (2011).
- 389 25. Kang, H. T., Lee, K. B., Kim, S. Y., Choi, H. R. & Park, S. C. Autophagy
- impairment induces premature senescence in primary human fibroblasts. *PLoS ONE*6, e23367 (2011).
- 392 26. Dörr, J. R. *et al.* Synthetic lethal metabolic targeting of cellular senescence in
- 393 cancer therapy. *Nature* **501**, 421–425 (2013).

- 394 27. Hewitt, G. et al. Telomeres are favoured targets of a persistent DNA damage
- response in ageing and stress-induced senescence. *Nat Commun* **3**, 708 (2012).
- 396 28. Correia-Melo, C. et al. Mitochondria are required for pro-ageing features of
- 397 the senescent phenotype. *EMBO J.* **35**, 724–742 (2016).
- 398 29. Jurk, D. *et al.* Chronic inflammation induces telomere dysfunction and
- accelerates ageing in mice. *Nat Commun* **2**, 4172 (2014).
- 400 30. Whitehead, J. C. et al. A clinical frailty index in aging mice: comparisons with
- 401 frailty index data in humans. J. Gerontol. A Biol. Sci. Med. Sci. 69, 621–632 (2014).
- 402 31. Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy
- 403 individuals. *Nature* **559**, 400–404 (2018).
- 404 32. Fumagalli, M. *et al.* Telomeric DNA damage is irreparable and causes
- 405 persistent DNA-damage-response activation. *Nat. Cell Biol.* **14**, 355–365 (2012).
- 406 33. Takamura, A. *et al.* Autophagy-deficient mice develop multiple liver tumors.
- 407 Genes Dev. 25, 795–800 (2011).
- 408 34. Karsli-Uzunbas, G. et al. Autophagy is required for glucose homeostasis and
- 409 lung tumor maintenance. *Cancer Discov* **4**, 914–927 (2014).
- 410 35. Trifunovic, A. *et al.* Premature ageing in mice expressing defective
- 411 mitochondrial DNA polymerase. *Nature* **429**, 417–423 (2004).
- 412 36. Kujoth, G. C. *et al.* Mitochondrial DNA mutations, oxidative stress, and
- 413 apoptosis in mammalian aging. *Science* **309**, 481–484 (2005).
- 414 37. Hansen, M., Rubinsztein, D. C. & Walker, D. W. Autophagy as a promoter of
- 415 longevity: insights from model organisms. *Nat. Rev. Mol. Cell Biol.* **19**, 579–593
- 416 (2018).
- 417 38. Guo, J. Y., Xia, B. & White, E. Autophagy-mediated tumor promotion. **155**,
- 418 1216–1219 (2013).
- 419 39. Rosenfeldt, M. T. *et al.* p53 status determines the role of autophagy in
- 420 pancreatic tumour development. *Nature* **504**, 296–300 (2013).

- 421 40. Qu, X. et al. Promotion of tumorigenesis by heterozygous disruption of the
- 422 beclin 1 autophagy gene. **112**, 1809–1820 (2003).
- 423 41. Yue, Z., Jin, S., Yang, C., Levine, A. J. & Heintz, N. Beclin 1, an autophagy
- 424 gene essential for early embryonic development, is a haploinsufficient tumor
- 425 suppressor. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 15077–15082 (2003).
- 426 42. Guo, J. Y. et al. Autophagy suppresses progression of K-ras-induced lung
- 427 tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27, 1447–1461
- 428 (2013).
- 429 43. Strohecker, A. M. *et al.* Autophagy sustains mitochondrial glutamine
- 430 metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 3, 1272–
- 431 1285 (2013).
- 432 44. Yang, A. *et al.* Autophagy Sustains Pancreatic Cancer Growth through Both
- 433 Cell-Autonomous and Nonautonomous Mechanisms. *Cancer Discov* 8, 276–287
- 434 (2018).
- 435 45. Lim, Y. M. *et al.* Systemic autophagy insufficiency compromises adaptation to
 436 metabolic stress and facilitates progression from obesity to diabetes. *Nat Commun* 5,
 437 4934 (2014).
- 438

439 Acknowledgements

440 We thank members of the Narita group, as well as K. Inoki of the University of 441 Michigan, for their insights and suggestions. We are grateful to the following CRUK 442 Cambridge Institute core facilities for advice and assistance: Histopathology, Light 443 Microscopy (in particular H. Zecchini), and BRU. Funding: This work was supported 444 by the University of Cambridge, Cancer Research UK and Hutchison Whampoa. The 445 M.N. lab was supported by a Cancer Research UK Cambridge Institute Core Grant 446 [C14303/A17197]. M.N. is also supported by The CRUK Early Detection Pump Priming 447 Awards [C20/A20976] and Medical Research Council [MR/M013049/1]. C.N.J.Y. is 448 supported by a DMU Early Career Fellowship. M.C.H.C is supported by grants from

449 The British Heart Foundation [FS/13/3/30038], [FS/18/19/33371], and 450 [RG/16/8/32388]. D.J. is funded by a Newcastle University Faculty of Medical Sciences 451 Fellowship and The Academy of Medical Sciences. J.P. was supported by the BBSRC 452 [BB/H022384/1] and [BB/K017314/1]. Author Contributions: L.D.C and M.N. 453 designed the research plan and interpreted the results. A.R.Y and C.N.J.Y isolated 454 skeletal muscle tissue. C.N.J.Y performed staining and analysis of muscle sections. 455 E.J.S and R.B are trained pathologists and reviewed all tissue slides. E.F and M.W 456 established and assisted with the frailty scoring. K.A.W and M.C.H.C performed serum cytokine analyses. D.J and J.F.P performed the TAF studies. L.D.C and M.N wrote the 457 458 manuscript, all authors viewed and commented on. Competing interests: None of the 459 authors have a competing interest to declare. Data and materials availability: All data 460 and materials are available in the manuscript or upon request.

462 Methods

463 Atg5i mouse maintenance and aging: The generation and initial characterization of 464 the Atg5i transgenic line has previously been described in detail¹³. Mice were 465 maintained on a mixed C57BI/6 X 129 background with littermate controls used in all 466 experiments. All experimental mice were maintained as heterozygous for both the 467 shRNA allele and CAG-rtTA3 alleles, whereas control littermates were lacking one of 468 the alleles. Guide sequences were as follows: Atg5i TATGAAGAAAGTTATCTGGGTA 469 ¹³; Atg5i 2 TTATTTAAAAATCTCTCACTGT. Mice were maintained in a specific 470 pathogen-free environment under a 12-h light/dark cycle, having free access to food 471 and water. These mice were fed either a laboratory diet (PicoLab Mouse Diet 20, 5R58) 472 or the same diet containing doxycycline at 200 ppm (PicoLab Mouse Diet, 5A5X). For 473 this study mice were aged for two months before doxycycline administration in the diet. 474 Mice were enrolled either to time-point study groups or long-term longevity cohorts 475 (LT- and R- groups). Experienced animal technicians checked mice daily in a blinded 476 fashion, and additionally mice were weighed and hand-checked on a weekly basis. 477 Mice found to be of deteriorating health were culled under the advice of senior animal 478 technicians if displaying end of life criteria. These signs include a combination of (1) 479 hunched body position with matted fur, (2) piloerection, (3) poor body condition (BC) 480 score (BC1 to 2), (4) failure to eat or drink, (5) cold to touch, and or (6) reduced mobility, 481 including severe balance disturbances and ataxia. In accordance with UK home office 482 regulations any mice suffering a 15% loss of body weight were also considered to be 483 at an end-point. Note that for LT- longevity cohorts a portion of control mice were culled 484 to generate age-matched littermate control tissue. These mice are marked as 485 censored events on the survival curve. For analysis mice were treated as alive up to 486 the point of their removal from the study where they are considered lost to follow-up 487 and are not included in the calculations of median longevity. All experiments were 488 performed in accordance with national and institutional guidelines, and the ethics 489 review committee of the University of Cambridge approved this study.

490

Frailty Scoring: Clinical frailty scoring was determined using the previously published
frailty index³⁰. A blinded researcher and animal technician performed all frailty scores
independently within the same 48 hr period and scores were compared afterwards to
ensure accuracy of phenotype scoring.

495

496 Pathology and Immunohistochemistry: Explanted tissues were fixed in 10% 497 neutral-buffered formalin solution for 24 hr and transferred to 70% ethanol. Tissues 498 were embedded in paraffin, cut in 3µm sections on poly-lysine coated slides, 499 deparaffinized, rehydrated, and stained with H&E. The PAS, Congo Red and Massons 500 Trichrome histochemical stains were performed according to established protocols. 501 An experienced pathologist reviewed all histology blinded for evidence of tumors and 502 tissue pathologies. For immunohistochemistry and tissue immunoflourescence 503 formalin-fixed paraffin-embedded samples were de-waxed and rehydrated. For anti-504 P21 (Santa Cruz, SC-6246; 1:500), and anti-TOM20 (Santa Cruz SC-11415, 1:500) 505 staining antigen unmasking was performed with citrate buffer (10 mM sodium citrate, 506 0.05% Tween 20, pH 6) in a pressure cooker for 5 min at 120°C. For P21 exogenous 507 peroxidases were quenched in 3% H2O2/PBS for 15 min and the remaining steps were 508 performed according to Vector Labs Mouse on Mouse staining kit (MP-2400). The 509 remaining antibodies were used at the following concentrations and ran on the Leica 510 Polymer Detection system (DS9800) with the Leica automated Bond platform: Anti-511 SQSTM1 (Enzo, BML-PW9860; 1:750), anti-KI67 (Bathyl Laboratories, IHC-00375; 512 1:1000), Anti-LC3 (Nanotools, LC3-5F10 0231-100, 1:400).

513

514 For TOM20 analysis the intensity of signal per entire muscle section was determined 515 and an average measurement of intensity per unit area calculated. Samples were then 516 plotted as a fold increase relative to the average intensity per unit of control muscle 517 sections

518

For kidney glomeruli size tissue sections were analysed using ImageScope[™] (Leica
Biosystems) and the cross-sectional area of ten glomeruli in the renal cortex was
reported per sample.

522

Western Blotting: Western blot analysis was performed as previously²³. Tissue 523 524 samples were homogenized with the Precellys 24 tissue homogenizer in laemmeli 525 buffer and samples ran on 12.5% or 15% gels. Protein was transferred to PVDF 526 membranes (Immobilon, Millipore), which was subsequently blocked for 1 hr at room 527 temperature (5% milk solution in TBS-Tween 0.1%) before incubating with primary 528 antibody at 4°C overnight. An appropriate HRP-conjugated secondary antibody was 529 incubated at room temperature for 1 hr. Western blots were visualized with 530 chemiluminsence reagents (Sigma, RPN2106). Antibodies were used at the following 531 concentrations: Anti-ATG5 (Abcam, ab108327; 1:1000), anti-LC3 (Abcam, ab192890; 532 1:1000), anti-ACTIN (Santa Cruz Biotechnology, I-19; 1:5000 [no longer commercially 533 available]), anti-P53 (Cell Signalling Technologies, Clone 1C12; 1:1000), anti-P21 534 (Santa Cruz, SC-6246; 1:1000), anti-Histone H3 (Abcam, ab1791; 1:5000), anti-P16 535 (Santa Cruz, SC-1207; 1:1000), anti-HMGA1 (Abcam, ab129153; 1:1000).

536

537 Blood and serum analysis: Whole blood composition was performed using the 538 Mythic Hematology Analyser to determine whole blood counts, immune composition, 539 and RDW. Mouse cytokines were determined using a cytometric bead array (BD 540 Biosciences, Catalogue number: 552364). Sera isolated from mice were analyzed by 541 the Core Biochemical Assay Laboratory (CBAL), Cambridge, UK for Alanine 542 Transferase (Siemens Healthcare), Albumin (Siemens Healthcare), Bilirubin (Siemens 543 Healthcare), and Creatinine (Siemens Healthcare) using automated Siemens 544 Dimension RxL and ExL analyzers.

545

546 **Telomere Associated DNA Damage Foci (TAF)**

547 Formalin-fixed paraffin-embedded liver sections were hydrated by incubation in 100% 548 Histoclear, 100, 95 and 2X 70% methanol for 5 min before washed in distilled water 549 for 2X 5 min. For antigen retrieval, the slides were placed in 0.1 M citrate buffer and 550 heated until boiling for 10 min. After cooling down to room temperature, the slides were 551 washed 2X with distilled water for 5 min. After blocking in normal goat serum (1:60) in 552 BSA/PBS, anti-y-H2A.X primary antibody (Cell Signalling Technologies, S139; 1:250) 553 was applied and incubated at 4 °C overnight. Slides were washed 3X in PBS, 554 incubated with secondary antibody for 30 min, washed three times in PBS and 555 incubated with Avidin DCS (1:500) for 20 min. Following incubation, slides were 556 washed three times in PBS and dehydrated with 70, 90 and 100% ethanol for 3 min 557 each. Sections were denatured for 5 min at 80 °C in hybridization buffer (70% 558 formamide (Sigma), 25 mM MgCl₂, 1 M Tris pH 7.2, 5% blocking reagent (Roche) 559 containing 2.5 µg ml⁻¹ Cy-3-labelled telomere specific (CCCTAA) peptide nuclei acid 560 probe (Panagene), followed by hybridization for 2 h at room temperature in the dark. 561 The slides were washed with 70% formamide in 2×SSC for 2X 15 min, followed by 562 2×SSC and PBS washes for 10 min. Sections were incubated with DAPI, mounted and 563 imaged. In depth Z stacking was used (a minimum of 40 optical slices with x100 564 objective) followed by Huygens (SVI) deconvolution.

565

566 Senescence associated beta-galactosidase staining

567 Whole tissue samples were washed in PBS (pH5.5) before being fixed in 0.5% 568 Glutaraldehyde overnight and washed 2X 15 min in PBS (pH5.5) at 4^oC. SA-β-gal 569 activity was assessed after incubation in X-Gal solution for 90 minutes at 37^oC.

570

571 **Muscle Morphopmetric Analysis:** Mice were sacrificed at the time points described 572 and dissected muscle was rapidly frozen in liquid nitrogen cooled isopentane to 573 maintain structure and minimize tissue artifacts. Experimental mice and age-matched

574 littermate controls were isolated at the same time to ensure processing was consistent 575 between groups. Frozen muscles were equilibrated in a cryostat chamber to -20°C 576 and cryosections 10-µm thick were then cut from the middle third of the sample and 577 collected on poly-L-lysine (0.5 mg/ml)-coated glass slides. Sections were allowed to 578 air dry and were then frozen at -80°C prior to use. Samples were brought to 4°C on ice 579 and fixed in a 4% w/v 0.45 mm filtered paraformaldehyde solution in 1 x PBS for 15 580 min at 4°C. PFA was removed by three 5 min washes in 1 x PBS, then blocked in 10% 581 v/v serum in 1 x PBST (0.01% Tween-20) for 1 hr at RT. Primary anti-dystrophin 582 antibody (Abcam, ab15277, 1:1000) was then applied in 1 x PBST containing 10% v/v 583 serum for 2 h at room temperature. Three 5-min PBST washes were applied before 584 secondary antibody conjugated to Alexa Fluor 647, with DAPI at 1:1000, incubation in 585 PBST and 10% v/v serum for 1 h at room temperature. Sections were finally washed 586 three times for 15 min before mounting in Vectorshield Antifade Mounting Medium 587 (Vector Labs). Whole cross-sections of TA muscles were produced via montaged 40x 588 magnification tile scans (Zeiss Axio Z1 Widefield system). Morphometric analysis was 589 performed using Fiji open source software as previously described (26461208). 590 Simultaneous DAPI nuclear stain was used for central nucleation count. PAX7 counts 591 were performed manually in a blinded fashion, a satellite cell was defined as having a 592 PAX7 positive nuclei within a LAMININ cell border staining. For immunostaining the 593 following antibodies were used anti-PAX7 PAX7 (DSHB, PAX7, 1:50), after pre-594 treatment with Vector Labs Mouse on Mouse Blocking Reagent (MKB-2213) according 595 to manufacturer's instructions and anti-LAMININ (Abcam, ab11576, 1:1000).

596 Figure Legends

597

598 **Figure 1: Autophagy inhibition decreases lifespan.**

599 a-c, LT-Atg5i mice on dox continuously from two months old display a reduced lifespan 600 in comparison to LT-Control as shown in survival graphs for (\mathbf{a}) combined (p<0.0001), 601 (b) male (p<0.0001), (c) female (p<0.0001) (Mantel-Cox test). Median survival (days 602 on dox) and mice per group are indicated. d-e, During this period LT-Atg5i mice also 603 display a reduced weight gain in both (d) male and (e) female cohorts. f, LT-Atg5i mice 604 also display an increased frequency of skin inflammation and eye infections in 605 comparison to age-matched LT-Control mice. g, Cardiac fibrosis was also evident in 606 LT-Atg5i mice. Representative images of H&E and Massons Trichrome are shown. 607 Scale bars,100 µm. h, Age-matched skinned mice. LT-Atq5i mice show kyphosis 608 (yellow dotted line traces the arch of the spine). They often displayed premature 609 greying (dotted rectangle). Arrows indicate the presence of inflammation.

610

611 Figure 2: LT-Atg5i mice present with accelerated aging phenotypes.

612 a, Extramedullary haematopoiesis is present in the spleens of LT-Atg5i mice in 613 comparison to age-matched controls. Scale bars, 100 µm. b, Composition of the 614 peripheral immune system in LT-Atq5i mice is reminiscent of old control mice. (n=5-6 615 mice per group). c, Six-month-old LT-Atg5i mice (four months dox treatment) displayed 616 increased serum levels of IL-6 and TNF (LT-Atg5i n=5, LT-Ctrl n=8; Mann Whitney 617 Test). **d-h**, LT-Atg5i mice display alterations in skeletal muscle after six-months of dox 618 treatment. (d) LT-Atg5i mice display a significant difference in minimum feret size (n= 619 4 R-Ctrl and 4 R-Atg5i, Mann Whitney test) and (e) cross-sectional area (n= 4 R-Ctrl 620 and 4 R-Atg5i, Mann Whitney test). LT-Atg5i mice also display a decrease in Pax7 621 nuclear positivity per fibre (f), an increase in central nucleation (g), and positivity for 622 the mitochondrial marker TOM20 (h), as determined by tissue immunofluorescence 623 (unpaired two-tailed Welches t-test; n= 4 R-Ctrl and 4 R-Atg5i). Error bars indicate

624 standard deviations. *p<0.05; **p<0.01, ***p<0.001

625

626 Figure 3: Autophagy inhibition drives senescence in vivo

627 a-d, Markers of senescence can also be seen across multiple tissues in our LT-Atg5i 628 cohorts treated with dox for four months including in (a) kidney, (b) heart, and (c) liver. 629 (d) LT-Atg5i livers stain positively for senescence associated β -galactosidase and p21 630 unlike age-matched control mice (scale bar, 25 µm). e, Six-month doxycycline treated 631 LT-Atg5i livers display an increase in the frequency and abundance of v-H2AX at 632 telomeres, a marker associated with increasing chronological age (unpaired two-tailed 633 t-test; n=5). f, A representative example image shown. Arrowheads point to TAF that 634 are magnified on the right of the image. Scale bar, 10 µm. Error bars indicate standard 635 deviation ***p<0.001

636

637 **Figure 4: Restoration of autophagy partially restores health-span**

638 a, Schematic of R-Atq5i study. Briefly two-month old mice are given dox to induce Atq5 639 downregulation for four months at which point they exhibit ageing-like phenotypes. Dox 640 is then removed and autophagy restored. **b**, Tissues from R-Atg5i mice with autophagy 641 restored for two months display evidence of ATG5 protein and autophagy restoration, 642 yet still stain positively for markers of senescence. c, Atg5i mice on dox for four months 643 and six months display increase frailty scores in comparison to controls (ARU, arbitrary 644 units). While R-Atg5i mice where autophagy has been restored for four months, display 645 a recovery (Two-way ANOVA with Tukey's correction for all comparisons, n=3-16). d, 646 Whole blood cell counts from R-Atg5i mice display no difference in comparison to age 647 matched R-Control mice (unpaired two-tailed t-test; n=11 per group). e, Inflammatory 648 serum cytokines IL6 and TNF are equivalent in R-Atg5i and R-Control mice two-649 months post dox removal (Mann Whitney test; n= 3 R-Ctrl and 4 R-Atg5i). f, Red blood 650 cell distribution width (RDW) is altered in aged autophagy-restored cohorts (four

months dox, eight months restoration) (unpaired two-tailed t-test; n=14 per group).

Error bars indicate standard deviation; NS denotes not significant. *p<0.05; **p<0.01,

- 653 ***p<0.001.
- 654

Figure 5: Restoration of autophagy does not reverse markers of aging

656 a, p62/Sqstm1 staining of R-Atq5i liver highlights the incomplete removal of 657 aggregates four months after autophagy restoration. Scale bars, 100 µm. b, The same 658 livers have a higher incidence of age associated pigmentation in comparison to age-659 matched control mice. (yellow arrow). c, TAF frequency and abundance also remains 660 elevated in R-Atg5i mice (unpaired two-tailed t-test; n= 4 R-Ctrl and 3 R-Atg5i). d-h. 661 Skeletal muscle analysis from four months dox treated and two months restored R-662 Atg5i mice. R-Atg5i muscle fibres continue to display significant alterations in (d) 663 minimum feret size (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test) and (e) cross-664 sectional area (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test), but with a recovery of 665 (f) central nucleation. (g) Pax7 nuclear positivity per fibre and (h) positivity for the 666 mitochondrial marker TOM20 displays a heterogeneous recovery pattern in these 667 mice, as measured by tissue immunofluorescence. (**f-h**, unpaired two-tailed Welches 668 t-test; n= 2 R-Ctrl and 4 R-Atg5i). Error bars indicate standard deviations. *p<0.05; 669 **p<0.01, ***p<0.001

670

Figure 6: R-Atg5i mice are associated with accelerated spontaneous tumor development

673 **a**, R-Atg5i mice on display a reduced lifespan in comparison to R-Control mice

674 (p<0.01). **b**, Increased frequency of spontaneous tumour formation in R-Atg5i cohorts

675 (p<0.001). **c**, Tumor spectrum in R-Atg5i mice versus R-Control mice. **d - e**,

676 Examples of R-Atg5i tumour histology. H&E staining and immunostaining of indicated

677 proteins. Scale bars, 100µm.

678

679 Supplementary Figure 1: Characterisation of LT-Atg5i mice

680 a, LT-Atg5i mice display no life-span associated sex bias (Red, LT-Atg5i Males; Purple, 681 LT-Atg5i Females; p=0.8). b, LT-Atg5i mouse weight plateau while LT-Control mice 682 continue to gain weight over their lifetime. c, Example of mouse suffering from 683 ulcerative dermatitis. d, Splenic weights were increased in LT-Atg5i mice in 684 comparison to age matched LT-Control mice. e, LT-Atg5i mice also display an increase 685 in liver weight. **f-h**, liver function of LT-Atg5i mice as determined using serum samples. 686 LT-Atg5i mice on dox for 4 months display (f) an increase in serum ALT and (g) a 687 decrease in serum albumin that is further exacerbated in a subset of LT-Atq5i EoL 688 individuals (yellow circles). (h) The only sample tested that displayed an increase in 689 serum bilirubin levels was also from a mouse displaying high levels of serum ALT and 690 low levels of serum album. Error bars indicate standard deviations. *p<0.05; **p<0.01, 691 ***p<0.001

692

693 **Supplementary Figure 2: Kidney alterations in LT-Atg5i mice**

694 (a) LT-cohorts treated with doxycycline for 6 months mice display no significant 695 differences in serum creatinine levels (unpaired two-tailed Welches t-test, NS denotes 696 not significant; n= 3 LT-Control and 4 LT-Atg5i). At death only a subset of LT-Atg5i 697 mice display an increase in serum creatinine levels. **b-f**, LT-Atg5i mouse kidneys 698 treated with doxycycline for 6 months present with (b) evidence of sclerotic glomeruli 699 determined using PAS stain that are also (c-d) enlarged and hypercelluar in 700 comparison to LT-Control (p=0.0479, unpaired two-tailed t-test; n= 4 LT-Control and 3 701 LT-Atg5i, the cross-sectional area of 10 randomly chosen glomeruli were measured 702 per mouse). (e) Congo red and (f) P62/Sqstm1 staining of LT-Atg5i mouse kidneys 703 treated with doxycycline for 6 months highlights an increase in protein aggregation not 704 present in age-matched LT-Control mice. g, Cardiac tissue from LT-Atg5i mice at death 705 was significantly heavier than age-matched LT-Control mice. (p=0.0108). Error bars 706 indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001

_	-	_
~	\mathbf{n}	-
	υ	

708 Supplementary Figure 3: Systemic alterations in LT-Atg5i mice

a, LT-Atg5i mice display evidence of widespread immune infiltration across multiple
tissues in comparison to age-matched controls. Scale bars,100 µm. b, White blood cell
counts (WBC) of LT-Control and LT-Atg5i mice treated with doxycycline for 4 months
(6 months old) (unpaired two-tailed Welches t-test, n=5-6 per group). c, Skeletal
muscle displays markers of senescence in LT-Atg5i cohorts on doxycycline for 4
months. **p<0.01

715

Supplementary Figure 4: Hypomorphic LT-Atg5i_2 mice also display aging

717 phenotypes

718 a-c, LT-Atg5i 2 mice phenotypically recapitulate premature ageing phenotypes 719 including (a) kyphosis, (b) increased frailty (ARU, arbitrary units; Mann-whitney n= 14 720 LT-Control and 5 LT-Atg5i_2 mice), and (c) reduced longevity. d-f However, Atg5i_2 721 mice appear to have a hypomorphic phenotype and do not recapitulate the phenotypes 722 found in Atg5 knock-out and LT-Atg5i. These include no evidence of (d) hepatomegaly 723 or (e) splenomegaly. (f) Correspondingly, p62/SQSTM1 and LC3 levels do not 724 accumulate to the same degree in LT-Atg5_2 mice treated with doxycycline for 6 725 weeks. Scale bars,100 µm. Error bars indicate standard deviations. *p<0.05

726

727 Supplementary Figure 5: Autophagy restoration reverses hepatomegaly and

728 splenomegaly

a, Splenic and b, liver weights from R-Atg5i mice exhibit evidence of recovery. c, In
addition R-Atg5i mice display a reduction in serum ALT levels (unpaired two-tailed
Welches t-test; n= 3-4 per cohort). d-f, R-Atg5i mice 4 months post dox removal display
evidence of recovery in the kidneys as determined by (d-e) normalisation of glomeruli
size appeared relative to age-matched controls (unpaired two-tailed Mann whitney,
n=3-4 mice per group) and (f) the absence of sclerosis. g, A partial recovery in serum

- albumin levels is also present in these mice unpaired two-tailed Welches t-test; n= 2-
- 9 per cohort). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001
- 737

738 Supplementary Figure 6: Autophagy restoration displays segmental rescue of

739 tissue phenotypes

- a-b, Skeletal muscle displays no rescue of phenotype once Atg5i mice are removed
 from dox. As determined by (a) minimal feret size, and (b) cross-sectional area.
 (unpaired two-tailed Welches t-test, n=3-5 per group). c, Cardiac fibrosis was still
 present in R-Atg5i mice 4 months post dox removal. Error bars indicate standard
- 744 deviations. *p<0.05
- 745

Supplementary Movie. 1: R-Atg5i mice 4 months post dox removal highlighting the stochastic response to autophagy restoration. All mice were treated on dox for 4 months before dox removal for 2 months. At this stage, 100 % of mice show kyphosis. The movie represents three examples with different levels of recovery. Mouse I exhibits little recovery, whereas mouse III looks normal with no sign of kyphosis. Mouse II appears active but with mild kyphosis.

Figure 1 _ Cassidy





Figure 1: Autophagy inhibition decreases lifespan.

a-c, LT-Atg5i mice on dox continuously from two months old display a reduced lifespan in comparison to LT-Control as shown in survival graphs for (**a**) combined (p<0.0001), (**b**) male (p<0.0001), (**c**) female (p<0.0001) (Mantel-Cox test). Median survival (days on dox) and mice per group are indicated. **d-e**, During this period LT-Atg5i mice also display a reduced weight gain in both (**d**) male and (**e**) female cohorts. **f**, LT-Atg5i mice also display an increased frequency of skin inflammation and eye infections in comparison to age-matched LT-Control mice. **g**, Cardiac fibrosis was also evident in LT-Atg5i mice. Representative images of H&E and Massons Trichrome are shown. Scale bars,100 μm. **h**, Age-matched skinned mice. LT-Atg5i mice show kyphosis (yellow dotted line traces the arch of the spine). They often displayed premature greying (dotted rectangle). Arrows indicate the presence of inflammation.





a, Extramedullary haematopoiesis is present in the spleens of LT-Atg5i mice in comparison to age-matched controls. Scale bars,100 μm. **b**, Composition of the peripheral immune system in LT-Atg5i mice is reminiscent of old control mice. (n=5-6 mice per group). **c**, Six-month-old LT-Atg5i mice (four months dox treatment) displayed increased serum levels of IL-6 and TNF (LT-Atg5i n=5, LT-Ctrl n=8; Mann Whitney Test). **d-h**, LT-Atg5i mice display alterations in skeletal muscle after six-months of dox treatment. (**d**) LT-Atg5i mice display a significant difference in minimum feret size (n= 4 R-Ctrl and 4 R-Atg5i, Mann Whitney test) and (**e**) cross-sectional area (n= 4 R-Ctrl and 4 R-Atg5i, Mann Whitney test). LT-Atg5i mice also display a decrease in Pax7 nuclear positivity per fibre (**f**), an increase in central nucleation (**g**), and positivity for the mitochondrial marker TOM20 (**h**), as determined by tissue immunofluorescence (unpaired two-tailed Welches t-test; n= 4 R-Ctrl and 4 R-Atg5i). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001




Figure 3 _ Cassidy

Figure 3: Autophagy inhibition drives senescence in vivo

a-d, Markers of senescence can also be seen across multiple tissues in our LT-Atg5i cohorts treated with dox for four months including in (**a**) kidney, (**b**) heart, and (**c**) liver. (**d**) LT-Atg5i livers stain positively for senescence associated β -galactosidase and p21 unlike age-matched control mice (scale bar, 25 µm). **e**, Six-month doxycycline treated LT-Atg5i livers display an increase in the frequency and abundance of γ -H2AX at telomeres, a marker associated with increasing chronological age (unpaired two-tailed t-test; n=5). **f**, A representative example image shown. Arrowheads point to TAF that are magnified on the right of the image. Scale bar, 10 µm. Error bars indicate standard deviation ***p<0.001




Figure 4 _ Cassidy

Figure 4: Restoration of autophagy partially restores health-span

a, Schematic of R-Atg5i study. Briefly two-month old mice are given dox to induce Atg5 downregulation for four months at which point they exhibit ageing-like phenotypes. Dox is then removed and autophagy restored. **b**, Tissues from R-Atg5i mice with autophagy restored for two months display evidence of ATG5 protein and autophagy restoration, yet still stain positively for markers of senescence. **c**, Atg5i mice on dox for four months and six months display increase frailty scores in comparison to controls (ARU, arbitrary units). While R-Atg5i mice where autophagy has been restored for four months, display a recovery (Two-way ANOVA with Tukey's correction for all comparisons, n=3-16). **d**, Whole blood cell counts from R-Atg5i mice display no difference in comparison to age matched R-Control mice (unpaired two-tailed t-test; n=11 per group). **e**, Inflammatory serum cytokines IL6 and TNF are equivalent in R-Atg5i and R-Control mice two-months post dox removal (Mann Whitney test; n= 3 R-Ctrl and 4 R-Atg5i). **f**, Red blood cell distribution width (RDW) is altered in aged autophagy-restored cohorts (four months dox, eight months restoration) (unpaired two-tailed t-test; n=14 per group). Error bars indicate standard deviation; NS denotes not significant. *p<0.05; **p<0.01, ***p<0.001.

Figure 5 _ Cassidy




Figure 5: Restoration of autophagy does not reverse markers of ageing

a, p62/Sqstm1 staining of R-Atg5i liver highlights the incomplete removal of aggregates four months after autophagy restoration. Scale bars,100 μ m. **b**, The same livers have a higher incidence of age associated pigmentation in comparison to age-matched control mice. (yellow arrow). **c**, TAF frequency and abundance also remains elevated in R-Atg5i mice (unpaired two-tailed t-test; n= 4 R-Ctrl and 3 R-Atg5i). **d-h**, Skeletal muscle analysis from four months dox treated and two months restored R-Atg5i mice. R-Atg5i muscle fibres continue to display significant alterations in (**d**) minimum feret size (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test) and (**e**) cross-sectional area (n= 4 R-Ctrl and 3 R-Atg5i, Mann Whitney test), but with a recovery of (**f**) central nucleation. (**g**) Pax7 nuclear positivity per fibre and (**h**) positivity for the mitochondrial marker TOM20 displays a heterogeneous recovery pattern in these mice, as measured by tissue immunofluorescence. (**f-h**, unpaired two-tailed Welches t-test; n= 2 R-Ctrl and 4 R-Atg5i). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001







Figure 6: R-Atg5i mice are associated with accelerated spontaneous tumor development

a, R-Atg5i mice on display a reduced lifespan in comparison to R-Control mice (p<0.01). **b**, Increased frequency of spontaneous tumour formation in R-Atg5i cohorts (p<0.001). **c**, Tumor spectrum in R-Atg5i mice versus R-Control mice. **d** - **e**, Examples of R-Atg5i tumour histology. H&E staining and immunostaining of indicated proteins. Scale bars, 100 μ m.


Supplementary Figure 1 _ Cassidy



Supplementary Figure 1: Characterisation of LT-Atg5i mice

a, LT-Atg5i mice display no life-span associated sex bias (Red, LT-Atg5i Males; Purple, LT-Atg5i Females; p=0.8). **b**, LT-Atg5i mouse weight plateau while LT-Control mice continue to gain weight over their lifetime. **c**, Example of mouse suffering from ulcerative dermatitis. **d**, Splenic weights were increased in LT-Atg5i mice in comparison to age matched LT-Control mice. **e**, LT-Atg5i mice also display an increase in liver weight. **f-h**, liver function of LT-Atg5i mice as determined using serum samples. LT-Atg5i mice on dox for 4 months display (**f**) an increase in serum ALT and (**g**) a decrease in serum albumin that is further exacerbated in a subset of LT-Atg5i EoL individuals (yellow circles). (**h**) The only sample tested that displayed an increase in serum bilirubin levels was also from a mouse displaying high levels of serum ALT and low levels of serum album. Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001


Supplementary Figure 2_ Cassidy



Supplementary Figure 2: Kidney alterations in LT-Atg5i mice

(a) LT-cohorts treated with doxycycline for 6 months mice display no significant differences in serum creatinine levels (unpaired two-tailed Welches t-test, NS denotes not significant; n= 3 LT-Control and 4 LT-Atg5i). At death only a subset of LT-Atg5i mice display an increase in serum creatinine levels. **b-f**, LT-Atg5i mouse kidneys treated with doxycycline for 6 months present with (**b**) evidence of sclerotic glomeruli determined using PAS stain that are also (**c-d**) enlarged and hypercelluar in comparison to LT-Control (p=0.0479, unpaired two-tailed t-test; n= 4 LT-Control and 3 LT-Atg5i, the cross-sectional area of 10 randomly chosen glomeruli were measured per mouse). (**e**) Congo red and (**f**) P62/Sqstm1 staining of LT-Atg5i mouse kidneys treated with doxycycline for 6 months highlights an increase in protein aggregation not present in age-matched LT-Control mice. (p=0.0108). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001


Supplementary Figure 3_ Cassidy



Supplementary Figure 3: Systemic alterations in LT-Atg5i mice


a, LT-Atg5i mice display evidence of widespread immune infiltration across multiple tissues in comparison to age-matched controls. Scale bars,100 μ m. **b**, White blood cell counts (WBC) of LT-Control and LT-Atg5i mice treated with doxycycline for 4 months (6 months old) (unpaired two-tailed Welches t-test, n=5-6 per group). **c**, Skeletal muscle displays markers of senescence in LT-Atg5i cohorts on doxycycline for 4 months. **p<0.01

Supplementary Figure 4 _ Cassidy



Supplementary Figure 4: Hypomorphic LT-Atg5i_2 mice also display aging phenotypes


a-c, LT-Atg5i_2 mice phenotypically recapitulate premature ageing phenotypes including (**a**) kyphosis, (**b**) increased frailty (ARU, arbitrary units; Mann-whitney n= 14 LT-Control and 5 LT-Atg5i_2 mice), and (**c**) reduced longevity. **d-f** However, Atg5i_2 mice appear to have a hypomorphic phenotype and do not recapitulate the phenotypes found in Atg5 knock-out and LT-Atg5i. These include no evidence of (**d**) hepatomegaly or (**e**) splenomegaly. (**f**) Correspondingly, p62/SQSTM1 and LC3 levels do not accumulate to the same degree in LT-Atg5_2 mice treated with doxycycline for 6 weeks. Scale bars,100 µm. Error bars indicate standard deviations. *p<0.05



Supplementary Figure 5 _ Cassidy

Supplementary Figure 5: Autophagy restoration reverses hepatomegaly and splenomegaly

a, Splenic and **b**, liver weights from R-Atg5i mice exhibit evidence of recovery. **c**, In addition R-Atg5i mice display a reduction in serum ALT levels (unpaired two-tailed Welches t-test; n=3-4 per cohort). **d-f**, R-Atg5i mice 4 months post dox removal display evidence of recovery in the kidneys as determined by (**d-e**) normalisation of glomeruli size appeared relative to age-matched controls (unpaired two-tailed Mann whitney, n=3-4 mice per group) and (**f**) the absence of sclerosis. **g**, A partial recovery in serum albumin levels is also present in these mice unpaired two-tailed Welches t-test; n=2-9 per cohort). Error bars indicate standard deviations. *p<0.05; **p<0.01, ***p<0.001



Supplementary Figure 6 _ Cassidy

Supplementary Figure 6: Autophagy restoration displays segmental rescue of tissue phenotypes

a-b, Skeletal muscle displays no rescue of phenotype once Atg5i mice are removed from dox. As determined by (**a**) minimal feret size, and (**b**) cross-sectional area. (unpaired two-tailed Welches t-test, n=3-5 per group). **c**, Cardiac fibrosis was still present in R-Atg5i mice 4 months post dox removal. Error bars indicate standard deviations. *p<0.05